Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

被引：75

作者：

Gaston, Czar Louie ^{[1
]}

Grimer, Robert J. ^{[1
]}

Parry, Michael ^{[1
]}

Stacchiotti, Silvia ^{[2
]}

Tos, Angelo Paolo Dei ^{[3
]}

Gelderblom, Hans ^{[4
]}

Ferrari, Stefano ^{[5
]}

Baldi, Giacomo G. ^{[6
]}

Jones, Robin L. ^{[7
,8
]}

Chawla, Sant ^{[9
]}

Casali, Paolo ^{[2
]}

LeCesne, Axel ^{[10
]}

Blay, Jean-Yves ^{[11
]}

Dijkstra, Sander P. D. ^{[4
]}

Thomas, David M. ^{[12
]}

Rutkowski, Piotr ^{[13
,14
]}

机构：

[1] Royal Orthopaed Hosp NHS Fdn Trust, Oncol Serv, Bristol Rd South, Birmingham B31 2AP, W Midlands, England

[2] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Milan, Italy

[3] Gen Hosp Treviso, Dept Anat Pathol, Treviso, Italy

[4] Leiden Univ, Med Ctr, Leiden, Netherlands

[5] Rizzoli Inst, Dept Oncol, Bologna, Italy

[6] S Stefano Civil Hosp, Dept Canc Med, Prato, Italy

[7] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[8] Royal Marsden Hosp, London, England

[9] Sarcoma Oncol Ctr, Santa Monica, CA USA

[10] Inst Gustave Roussy, Villejuif, France

[11] Ctr Leon Berard, Lyon, France

[12] Garvan Inst Med Res, Sydney, NSW, Australia

[13] Marie Curie Sklodowska Univ, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland

[14] Inst Oncol, Warsaw, Poland

来源：

CLINICAL SARCOMA RESEARCH | 2016年 / 6卷

关键词：

Giant cell tumor of bone; Denosumab; Safety; Neoadjuvant; Inoperable; Surgery;

D O I：

10.1186/s13569-016-0056-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension to allow for less morbid surgery. The role of Denosumab for conventional limb GCT of bone is yet to be defined. Further studies are required to determine whether local recurrence rates will be decreased with the adjuvant use of Denosumab along with surgery. The long term use and toxicity of this agent is unknown as is the proportion of patients with primary or secondary resistance. It is advised that complicated cases of GCT requiring Denosumab treatment should be referred and followed up at expert centres. Collaborative studies involving further clinical trials and rigorous data collection are strongly recommended to identify the optimum use of this drug.

引用

页数：6

共 56 条

[1] Denosumab Chemotherapy for Recurrent Giant-Cell Tumor of Bone: A Case Report of Neoadjuvant Use Enabling Complete Surgical Resection [J].

Agarwal, Amit ;

Larsen, Brandon T. ;

Buadu, Lawrence D. ;

Dunn, Jack ;

Crawford, Russell ;

Daniel, Jonathan ;

Bishop, Maria C. .

CASE REPORTS IN ONCOLOGICAL MEDICINE, 2013, 2013

[2] An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab [J].

Akaike, Keisuke ;

Suehara, Yoshiyuki ;

Takagi, Tatsuya ;

Kaneko, Kazuo ;

Saito, Tsuyoshi .

SKELETAL RADIOLOGY, 2014, 43 (12) :1767-1772

[3] A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab [J].

Aponte-Tinao, Luis A. ;

Piuzzi, Nicolas S. ;

Roitman, Pablo ;

Farfalli, German L. .

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2015, 473 (09) :3050-3055

[4] RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone [J].

Atkins, Gerald J. ;

Kostakis, Panagiota ;

Vincent, Cristina ;

Farrugia, Amanda N. ;

Houchins, Jeffrey P. ;

Findlay, David M. ;

Evdokiou, Andreas ;

Zannettino, Andrew C. W. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (09) :1339-1349

[5] Giant cell tumor of bone: treatment and outcome of 214 cases [J].

Balke, Maurice ;

Schremper, Laura ;

Gebert, Carsten ;

Ahrens, Helmut ;

Streitbuerger, Arne ;

Koehler, Gabriele ;

Hardes, Jendrik ;

Gosheger, Georg .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (09) :969-978

[6]

Balke Maurice, 2012, Sarcoma, V2012, P410973, DOI 10.1155/2012/410973

[7] Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone [J].

Behjati, Sam ;

Tarpey, Patrick S. ;

Presneau, Nadege ;

Scheipl, Susanne ;

Pillay, Nischalan ;

Van Loo, Peter ;

Wedge, David C. ;

Cooke, Susanna L. ;

Gundem, Gunes ;

Davies, Helen ;

Nik-Zainal, Serena ;

Martin, Sancha ;

McLaren, Stuart ;

Goodie, Victoria ;

Robinson, Ben ;

Butler, Adam ;

Teague, Jon W. ;

Halai, Dina ;

Khatri, Bhavisha ;

Myklebost, Ola ;

Baumhoer, Daniel ;

Jundt, Gernot ;

Hamoudi, Rifat ;

Tirabosco, Roberto ;

Amary, M. Fernanda ;

Futreal, P. Andrew ;

Stratton, Michael R. ;

Campbell, Peter J. ;

Flanagan, Adrienne M. .

NATURE GENETICS, 2013, 45 (12) :1479-U105

[8] Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study [J].

Bhatia, Sumita ;

Miszczyk, Leszek ;

Roelandts, Martine ;

Nguyen, Tan Dat ;

Boterberg, Tom ;

Poortmans, Phillip ;

Vallow, Laura ;

Dincbas, Fazilet O. ;

Lassen-Ramshad, Yasmin ;

Botros, Maikel ;

Miller, Robert C. .

RARE TUMORS, 2011, 3 (04) :150-152

[9] The role and biology of cryosurgery in the treatment of bone tumors - A review [J].

Bickels, J ;

Meller, I ;

Shmookler, BM ;

Malawer, MM .

ACTA ORTHOPAEDICA SCANDINAVICA, 1999, 70 (03) :308-315

[10] Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone [J].

Branstetter, Daniel G. ;

Nelson, Scott D. ;

Manivel, J. Carlos ;

Blay, Jean-Yves ;

Chawla, Sant ;

Thomas, David M. ;

Jun, Susie ;

Jacobs, Ira .

CLINICAL CANCER RESEARCH, 2012, 18 (16) :4415-4424

← 1 2 3 4 5 6 →